Skip to main content
Clinical Trials/NCT06194045
NCT06194045
Recruiting
Not Applicable

A Randomized, Double-blinded Nutritional Study to Determine the Effect of a Concentrated Cetoleic Acid Fish Oil on Atopic Dermatitis

Møreforsking AS1 site in 1 country60 target enrollmentDecember 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atopic Dermatitis
Sponsor
Møreforsking AS
Enrollment
60
Locations
1
Primary Endpoint
POEM
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Atopic Dermatitis is associated with pronounced changes in the lipid composition in the skin. The lipid changes are influenced by and contributing to both the inflammatory circuit and the impaired barrier as well as changes in the skin microbiome This nutritional study will investigate the effect of long-chain monounsaturated fatty acid Cetoleic acid on atoptic dermatitis. Earlier studies have shown a anti-inflammatory effect of celoteic acid.

Detailed Description

Women and men will be recruited to a placebo or a cetoleic-rich fish oil group and be examined for the effect on atopic dermatitis before, during and after the study period.

Registry
clinicaltrials.gov
Start Date
December 1, 2023
End Date
October 10, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Women and men 18-80 years of age.
  • Diagnosed with active mild to moderate atopic dermatitis with an EASI of 1.1- 21.
  • Willing to refrain from oil supplements (omega-3, borage, evening primrose, etc.) for 1 month before study begin (washout) and during the study
  • Willing to take the study supplement for 6 months

Exclusion Criteria

  • Known allergy to fish products
  • Subjects known to be pregnant or breast feeding
  • Subjects perceiving systemically administered medication for AD (other than topical)
  • Subjects with auto-immune diseases (except asthma and seasonal/perennial rhinitis)
  • Subjects with a diagnosis of other skin diseases

Outcomes

Primary Outcomes

POEM

Time Frame: 6 months

Change in POEM (Patient Oriented Eczema Measure)

EASI

Time Frame: 6 months

Change in EASI (Eczema Area and Serverity Index) POEM).

DQLI

Time Frame: 6 months

Change in DQLI

Itch Numerical Rating Scale (NRS)

Time Frame: 6 months

Change in experienced itch on average the last 24 hours, and how the worst itch in the past 24 hours was. Scale from 0 (no itch) to 10 (worst imaginable itch).

Secondary Outcomes

  • Lipid compositions in skin(6 months)
  • Inflammation in skin(6 months)
  • TEWL(6 months)
  • Blood lipids(6 months)
  • Cetoleic acid with EASI parameters(6 months)
  • Omega-3 index with EASI parameters(6 months)
  • Fatty acid composition in red blood cells(6 months)
  • Hydroxylated omega-3 fatty acids in plasma(6 months)

Study Sites (1)

Loading locations...

Similar Trials